Polyrizon Ltd. (PLRZ) Stock Analysis & Investment Frameworks
Polyrizon Ltd. (PLRZ) stock analysis on Invetso. Review Polyrizon Ltd.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Polyrizon Ltd. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
Polyrizon Ltd. Key Financial Metrics
- Market Cap: $13.01M
- Revenue: $N/A
- ROE: -24.10%
- ROIC: -52.17%
- Dividend Yield: N/A
About Polyrizon Ltd.
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
Polyrizon Ltd. Investment Frameworks
Invetso analyzes Polyrizon Ltd. (PLRZ) across the following frameworks:
- Polyrizon Ltd. 10Y Growth Potential
- Polyrizon Ltd. Scenario Analysis
- Polyrizon Ltd. Risks & Opportunities
- Polyrizon Ltd. Economic Moat
- Polyrizon Ltd. Business Model
- Polyrizon Ltd. Management
- Polyrizon Ltd. SWOT Analysis
- Polyrizon Ltd. Porter's 5 Forces
- Polyrizon Ltd. PESTLE Analysis
- Polyrizon Ltd. ESG Analysis